CLASSIFY-OMM: Multicenter Rare Disease Cohort for T-Stage Reclassification and Molecular Subtyping-Based Precision Therapy in Oral Mucosal Melanoma

ConditionsMucosal Melanoma of the Head and Neck Oral Melanoma

Trial statusNot yet recruiting

Trial phaseNot listed

Trial typeObservational

Biological sexAll

Age18+

SponsorShanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University

About this trial

This bidirectional cohort study (retrospective + prospective) focuses on three key challenges in oral mucosal melanoma (OMM): clinical staging based on depth of invasion (DOI), molecular subtyping, and precision therapy. By integrating DOI-driven T-stage reclassification, genomic profiling, and longitudinal follow-up, we aim to build a population-specific, high-quality evidence resource to support refined staging, CDK4-targeted treatment, and prognostic modeling for Chinese OMM patients.

Eligibility criteria

Qualifiers

Histopathologically confirmed primary oral mucosal melanoma (WHO criteria);

Disqualifiers

Primary melanoma originating from skin, eye, esophagus, or other non-oral mucosal sites;

Trial design

Treatments tested in this trial

Not listed

Trial groups

1,100 Participants

are grouped into 1 trial group

Sponsors and collaborators

Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University

Lead sponsor

Source ClinicalTrials.gov